Clifford Swan Investment Counsel LLC Sells 14,923 Shares of Bristol-Myers Squibb (NYSE:BMY)

Clifford Swan Investment Counsel LLC lessened its holdings in Bristol-Myers Squibb (NYSE:BMY) by 3.4% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 423,824 shares of the biopharmaceutical company’s stock after selling 14,923 shares during the quarter. Clifford Swan Investment Counsel LLC’s holdings in Bristol-Myers Squibb were worth $21,746,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Metis Global Partners LLC lifted its holdings in shares of Bristol-Myers Squibb by 17.2% in the 4th quarter. Metis Global Partners LLC now owns 119,251 shares of the biopharmaceutical company’s stock worth $6,119,000 after buying an additional 17,479 shares during the period. Gallacher Capital Management LLC boosted its stake in shares of Bristol-Myers Squibb by 57.1% during the fourth quarter. Gallacher Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock valued at $403,000 after purchasing an additional 2,855 shares in the last quarter. Sheets Smith Wealth Management increased its holdings in Bristol-Myers Squibb by 3.2% during the fourth quarter. Sheets Smith Wealth Management now owns 62,008 shares of the biopharmaceutical company’s stock valued at $3,182,000 after buying an additional 1,917 shares during the period. National Bank of Canada FI raised its stake in Bristol-Myers Squibb by 88.4% in the fourth quarter. National Bank of Canada FI now owns 2,827,499 shares of the biopharmaceutical company’s stock worth $149,176,000 after buying an additional 1,326,387 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC lifted its holdings in Bristol-Myers Squibb by 12.8% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 6,336 shares of the biopharmaceutical company’s stock worth $325,000 after buying an additional 720 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Stock Performance

NYSE BMY traded up $0.29 on Friday, hitting $43.99. 12,104,489 shares of the company’s stock traded hands, compared to its average volume of 14,314,010. The firm’s 50-day moving average price is $50.37 and its two-hundred day moving average price is $50.65. The firm has a market capitalization of $89.17 billion, a PE ratio of -14.19, a P/E/G ratio of 14.82 and a beta of 0.45. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. Bristol-Myers Squibb has a 1-year low of $43.33 and a 1-year high of $69.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The company had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.05 earnings per share. As a group, analysts expect that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 5.46%. The ex-dividend date of this dividend was Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Barclays reduced their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. BMO Capital Markets cut their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. Finally, Wells Fargo & Company upped their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.